Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Volvalerelactones A to preparation of drug for treating atherosclerosis

A technology for atherosclerosis and atherosclerosis in rats, which is applied in the directions of drug combination, pill delivery, cardiovascular system diseases, etc., can solve the problems such as the etiology and pathogenesis have not been fully elucidated, and there are no preventive measures and therapeutic drugs.

Inactive Publication Date: 2016-03-09
ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Atherosclerosis (AS) is the main pathological basis of cardiovascular and cerebrovascular diseases. So far, its etiology and pathogenesis have not been fully elucidated, so there are no concise and effective prevention measures and therapeutic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Volvalerelactones A to preparation of drug for treating atherosclerosis
  • Application of Volvalerelactones A to preparation of drug for treating atherosclerosis
  • Application of Volvalerelactones A to preparation of drug for treating atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Embodiment 1: the preparation of the compound Volvalerelactones A tablet involved in the present invention:

[0017] Take 5 grams of compound Volvalerelactones A, add 195 grams of dextrin, mix well, and make 1000 tablets with a conventional tablet machine.

Embodiment 2

[0018] Embodiment 2: the preparation of compound Volvalerelactones A capsules involved in the present invention:

[0019] Get 5 grams of compound Volvalerelactones A, add 195 grams of starch, mix evenly, and make 1000 capsules.

[0020] The following pharmacodynamic experiments will further illustrate its drug activity.

[0021] The present invention discloses the effect of Volvalerelactones A on atherosclerosis through cell level research and establishment of atherosclerosis model.

[0022] The present invention gives Volvalerelactones A through oral and intravenous injection, which can significantly reduce plaque area / intima area (%), intima thickness (um) / media thickness (%) in atherosclerotic rats; Ester, total cholesterol and low-density lipoprotein content decreased, indicating that Volvalerelactones A can treat atherosclerosis.

[0023] Materials and Methods

[0024] 1. Experimental materials:

[0025] 1.1 Animals and feed

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of Volvalerelactones A to preparation of a drug for treating atherosclerosis. Volvalerelactones A can achieve the atherosclerosis resisting effect by regulating blood lipids and protecting endothelial cells. The atherosclerosis-resisting drug prepared from Volvalerelactones A has a good treatment effect on atherosclerosis and can be used for resisting atherosclerosis of human or animals. The invention discloses the application of Volvalerelactones A to preparation of the drug resisting atherosclerosis for the first time, as the skeleton type is a brand-new skeleton type, Volvalerelactones A has unexpected inhibitory activity for atherosclerosis, it is impossible to reveal the clue through other compounds, and Volvalerelactones A has outstanding substantive advantages and makes great progress in resisting atherosclerosis.

Description

technical field [0001] The invention relates to a new application of compound Volvalerelactones A, in particular to the application of Volvalerelactones A in the preparation of drugs for treating atherosclerosis. Background technique [0002] Cardiovascular and cerebrovascular diseases are the most serious diseases that endanger human health and life in the contemporary era. They are common and frequently-occurring diseases among middle-aged and elderly people. Atherosclerosis (AS) is the main pathological basis of cardiovascular and cerebrovascular diseases. So far, its etiology and pathogenesis have not been fully elucidated, so there are no concise and effective prevention measures and therapeutic drugs. [0003] The compound Volvalerelactones A involved in the present invention is a brand new skeleton type compound published in 2013 (Peng-Cheng Wang, et al., Volvalerelactones A and B, Two New Sesquiterpenoid Lactones with Unprecedented Skeleton from Valeriana officinalis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61P9/10
CPCA61K31/366A61K9/2059A61K9/4866
Inventor 田丽华
Owner ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com